Skip to main content

Letairis FDA Approval History

FDA Approved: Yes (First approved June 15, 2007)
Brand name: Letairis
Generic name: ambrisentan
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: Pulmonary Arterial Hypertension

Letairis (ambrisentan) is an endothelin receptor antagonist (ERA) indicated for the once-daily oral treatment of pulmonary arterial hypertension.

Development timeline for Letairis

DateArticle
Oct  2, 2015Approval FDA Approves New Treatment Combination of Gilead’s Letairis with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1)
Jun 18, 2007Approval U.S. Food and Drug Administration Approves Gilead's Letairis (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Feb 16, 2007Gilead's New Drug Application for Ambrisentan Receives Priority Review Status
Dec 19, 2006Gilead Submits NDA To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

See also

Letairis (ambrisentan) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer